An existing antibiotic may improve TB treatment

Tuberculosis (TB) and human immunodeficiency virus (HIV) are both global epidemics that claim many people's lives each year. The bacterium Mycobacterium tuberculosis (Mtb) is the cause agent of TB. According to the Centers for Disease Control and Prevention (CDC), in 2015, TB affected 10.4 million people and was responsible for 1.8 million deaths worldwide.

Prognosis of TB has greatly improved over the past several decades. If the correct drugs are taken for the right amount of time, more than 90% of all TB cases can be cured. TB treatment usually includes multiple antibiotics, such as isoniazid, rifampin, ethambutol, and pyrazinamide.

However, TB in people with HIV is much more difficult to treat. People living with HIV are 24-28 times more likely to develop TB than people without HIV, says the WHO. This is because HIV infection weakens the immune system. TB is the leading cause of death among HIV-infected people. Antibiotics for TB may interact with antiretroviral therapy (ART) drugs used to treat HIV, leading to a condition called tuberculosis-immune reconstitution inflammatory syndrome (TB-IRIS). TB-IRIS is characterized by an excessive immune response against the Mtb bacteria, which causes further lung damage. But the underlying mechanism is not well-defined.

Recently, scientists from the University of Cape Tow, in collaboration with several other institutions, have identified differences in immune responses between TB patients with and without HIV. Their findings, which are published 5 May 2017 in Clinical Infectious Diseases, may improve the efficacy of current TB therapies.

Previous studies have shown that matrix metalloproteinases (MMPs), a family of enzymes responsible for degrading the main structural protein called collagen, may drive tissue destruction in TB. In this study, lead researcher Naomi Walker and colleagues measured MMP concentrations in sputum and plasma in HIV–infected and –uninfected TB patients and controls.

They found that MMP activity differed between HIV–infected and –uninfected TB patients and was related to specific TB clinical phenotypes. Patients with HIV/TB co-infection had lower lung MMP concentrations and milder lung damage than TB patients without HIV. Additionally, TB patients who were most infectious with worse lung damage had the highest MMP levels. Collectively, the results indicate that MMP activity is associated with lung damage.

Further experiments in vitro showed that the MMP inhibitor doxycycline could suppress matrix destruction induced by TB, suggesting that MMP inhibition is a potential host-directed therapy strategy for TB. Doxycycline is an antibiotic that is already used to treat infections caused by bacteria and protozoa. This study highlights the potential use of doxycycline in the prevention and treatment of TB.
About news
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1